A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects with Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists

Study identifier:D6830C00001

ClinicalTrials.gov identifier:NCT05110976

EudraCT identifier:2021-004000-18

CTIS identifier:N/A

Study Complete

Official Title

Phase I, Randomised, Blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD8630 in Healthy Adult Subjects (Part A) and Adults with Asthma on Medium to High Dose Inhaled Corticosteroids and Long-acting Beta-agonists (Part B)

Medical condition

asthma

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD8630, Placebo

Sex

All

Actual Enrollment

181

Study type

Interventional

Age

18 Years - 75 Years

Date

Study Start Date: 16 Dec 2021
Primary Completion Date: 02 Aug 2023
Study Completion Date: 02 Aug 2023

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Other

Verification:

Verified 01 Oct 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria